Literature DB >> 21951728

Poorer ART outcomes with increasing age at a large public sector HIV clinic in Johannesburg, South Africa.

Mhairi Maskew1, Alana T Brennan, A Patrick MacPhail, Ian M Sanne, Matthew P Fox.   

Abstract

BACKGROUND: As the current HIV-positive population ages, the absolute number of patients >50 years on treatment is increasing.
METHODS: We analyze the differences in treatment outcomes by age category (18-29, 30-39, 40-49, 50-59, and ≥ 60) among 9139 HIV-positive adults initiating ART in South Africa.
RESULTS: The adjusted hazard ratios (HRs) for all-cause mortality increased with increasing age, with the strongest association in the first 12 months of follow-up among patients 50 to 59 years (HR 1.67; 95% confidence interval [CI]: 1.24-2.23) versus those <30 years. However, patients 50 to 59 years were less likely to be lost during 24 months on antiretroviral therapy ([ART] HR 0.75; 95% CI: 0.59-0.94) versus patients <30 years. By 6 and 12 months on treatment, older patients were less likely to increase their CD4 count by ≥ 50 cells/mm(3).
CONCLUSION: Although older patients are at higher risk of mortality and have poorer immunological responses than their younger counterparts, they are more likely to adhere to care and treatment in the first 24 months on ART.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21951728      PMCID: PMC3272319          DOI: 10.1177/1545109711421641

Source DB:  PubMed          Journal:  J Int Assoc Physicians AIDS Care (Chic)        ISSN: 1545-1097


  37 in total

1.  Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study.

Authors:  J P Viard; A Mocroft; A Chiesi; O Kirk; B Røge; G Panos; N Vetter; J N Bruun; M Johnson; J D Lundgren
Journal:  J Infect Dis       Date:  2001-03-26       Impact factor: 5.226

2.  Response to highly active antiretroviral therapy in HIV-infected patients aged 60 years or older after 24 months follow-up.

Authors:  H Knobel; A Guelar; G Valldecillo; A Carmona; A González; J L López-Colomés; P Saballs; J L Gimeno; A Díez
Journal:  AIDS       Date:  2001-08-17       Impact factor: 4.177

3.  A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.

Authors:  Calvin J Cohen; Susan Hunt; Michael Sension; Charles Farthing; Marcus Conant; Susan Jacobson; Jeffrey Nadler; Werner Verbiest; Kurt Hertogs; Michael Ames; Alex R Rinehart; Neil M Graham
Journal:  AIDS       Date:  2002-03-08       Impact factor: 4.177

4.  Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study.

Authors:  T E Yamashita; J P Phair; A Muñoz; J B Margolick; R Detels; S J O'Brien; J W Mellors; S M Wolinsky; L P Jacobson
Journal:  AIDS       Date:  2001-04-13       Impact factor: 4.177

5.  Older HIV-positive patients in the era of highly active antiretroviral therapy: changing of a scenario.

Authors:  Mario Tumbarello; Ricardo Rabagliati; Katleen De Gaetano Donati; Silvia Bertagnolio; Enrica Tamburrini; Evelina Tacconelli; Roberto Cauda
Journal:  AIDS       Date:  2003-01-03       Impact factor: 4.177

6.  Antiretroviral treatment and advanced age: epidemiologic, laboratory, and clinical features in the elderly.

Authors:  Roberto Manfredi; Leonardo Calza; Davide Cocchi; Francesco Chiodo
Journal:  J Acquir Immune Defic Syndr       Date:  2003-05-01       Impact factor: 3.731

7.  Aging and HIV infection: a comparison between older HIV-infected persons and the general population.

Authors:  Nur F Onen; E Turner Overton; Warren Seyfried; Emily R Stumm; Mariea Snell; Kristin Mondy; Pablo Tebas
Journal:  HIV Clin Trials       Date:  2010 Mar-Apr

8.  Clinical experience with human immunodeficiency virus-infected older patients in the era of effective antiretroviral therapy.

Authors:  Richard M Grimes; Max E Otiniano; Maria C Rodriguez-Barradas; Dejian Lai
Journal:  Clin Infect Dis       Date:  2002-05-08       Impact factor: 9.079

Review 9.  Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review.

Authors:  Matthew P Fox; Sydney Rosen
Journal:  Trop Med Int Health       Date:  2010-06       Impact factor: 2.622

10.  Greater effect of highly active antiretroviral therapy on survival in people aged > or =50 years compared with younger people in an urban observational cohort.

Authors:  John L Perez; Richard D Moore
Journal:  Clin Infect Dis       Date:  2003-01-06       Impact factor: 9.079

View more
  30 in total

1.  Operationalizing early antiretroviral therapy in HIV-infected in-patients with opportunistic infections including tuberculosis.

Authors:  H Sunpath; C Edwin; N Chelin; S Nadesan; R Maharaj; Y Moosa; L Smeaton; R Court; S Knight; E Gwyther; R A Murphy
Journal:  Int J Tuberc Lung Dis       Date:  2012-07       Impact factor: 2.373

2.  Barriers to Retention in Care are Overcome by Adolescent-Friendly Services for Adolescents Living with HIV in South Africa: A Qualitative Analysis.

Authors:  Brian C Zanoni; Thobekile Sibaya; Chelline Cairns; Jessica E Haberer
Journal:  AIDS Behav       Date:  2019-04

3.  Age at antiretroviral therapy initiation predicts immune recovery, death, and loss to follow-up among HIV-infected adults in urban Zambia.

Authors:  Michael J Vinikoor; Jessica Joseph; Jonas Mwale; Melissa A Marx; Fastone M Goma; Lloyd B Mulenga; Jeffrey S A Stringer; Joseph J Eron; Benjamin H Chi
Journal:  AIDS Res Hum Retroviruses       Date:  2014-08-05       Impact factor: 2.205

4.  Cohort profile: the Themba Lethu Clinical Cohort, Johannesburg, South Africa.

Authors:  Matthew P Fox; Mhairi Maskew; A Patrick MacPhail; Lawrence Long; Alana T Brennan; Daniel Westreich; William B MacLeod; Pappie Majuba; Ian M Sanne
Journal:  Int J Epidemiol       Date:  2012-03-20       Impact factor: 7.196

5.  Age in antiretroviral therapy programmes in South Africa: a retrospective, multicentre, observational cohort study.

Authors:  Morna Cornell; Leigh F Johnson; Michael Schomaker; Frank Tanser; Mhairi Maskew; Robin Wood; Hans Prozesky; Janet Giddy; Kathryn Stinson; Matthias Egger; Andrew Boulle; Landon Myer
Journal:  Lancet HIV       Date:  2015-08-04       Impact factor: 12.767

6.  Aging with HIV in Africa: the challenges of living longer.

Authors:  Joel Negin; Till Bärnighausen; Jens D Lundgren; Edward J Mills
Journal:  AIDS       Date:  2012-07-31       Impact factor: 4.177

7.  HIV treatment cascade for older adults in rural South Africa.

Authors:  Julia K Rohr; Jennifer Manne-Goehler; Francesc Xavier Gómez-Olivé; Ryan G Wagner; Molly Rosenberg; Pascal Geldsetzer; Chodziwadziwa Kabudula; Kathleen Kahn; Stephen Tollman; Till Bärnighausen; Joshua A Salomon
Journal:  Sex Transm Infect       Date:  2019-06-26       Impact factor: 3.519

8.  Longitudinal interrelationship between HIV viral suppression, maternal weight change, breastfeeding, and length in HIV-exposed and uninfected infants participating in the Kabeho study in Kigali, Rwanda.

Authors:  Charlotte Lane; Linda Adair; Emily Bobrow; Gilles F Ndayisaba; Anita Asiimwe; Placidie Mugwaneza
Journal:  Ann Epidemiol       Date:  2020-08-15       Impact factor: 3.797

9.  Comparison of cohort characteristics in Central Africa International Epidemiology Databases to Evaluate AIDS and Demographic Health Surveys: Rwanda and Burundi.

Authors:  Anna Mageras; Ellen Brazier; Théodore Niyongabo; Gad Murenzi; Jean D'Amour Sinayobye; Adebola A Adedimeji; Christella Twizere; Elizabeth A Kelvin; Kathryn Anastos; Denis Nash; Heidi E Jones
Journal:  Int J STD AIDS       Date:  2021-02-03       Impact factor: 1.359

10.  Impact of Efavirenz Metabolism on Loss to Care in Older HIV+ Africans.

Authors:  Jessie Torgersen; Scarlett L Bellamy; Bakgaki Ratshaa; Xiaoyan Han; Mosepele Mosepele; Athena F Zuppa; Marijana Vujkovic; Andrew P Steenhoff; Gregory P Bisson; Robert Gross
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-04       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.